You Are Here    News

News
Vitamin D deficiency reduces statin potency, increases risk of muscle pain in people with HIV
by Keith Alcorn, 2017-01-18 07:30
People living with HIV who take statins are less likely to experience cholesterol reductions and more likely to develop painful muscle damage as a side effect if they have vitamin D deficiency, studies published this month in two journals show. Statins are widely prescribed to reduce LDL cholesterol levels and so

Tenofovir alafenamide approved for hepatitis B in Europe
by Liz Highleyman, 2017-01-17 07:30
The European Commission this week granted marketing authorisation for tenofovir alafenamide, to be sold under the brand name Vemlidy, for the treatment of chronic hepatitis B virus (HBV) infection, according to an announcement from Gilead Sciences. Tenofovir disoproxil fumarate or TDF (Viread), approved in 2002, is one of the most effective

People taking ART in the UK have an accurate understanding of their viral load
by Michael Carter, 2017-01-16 10:30
The vast majority of people taking antiretroviral therapy (ART) in the UK have an accurate knowledge of their current viral load (VL) level, investigators report in HIV Medicine. Overall, 96% of people who told researchers their viral load was undetectable had a clinic-recorded viral load below 50 copies/ml, with 99%

ART-treated patients in UK have an accurate understanding of their viral load
by Michael Carter, 2017-01-16 10:30
The vast majority of antiretroviral (ART)-treated patients in the UK have an accurate knowledge of their current viral load (VL) level, investigators report in HIV Medicine. Overall, 96% of patients who told researchers their viral load was undetectable had a clinic-recorded viral load below 50 copies/ml, with 99% having a

Implants and injectables: PrEP in the future
by Keith Alcorn, 2017-01-13 07:00
Last month’s announcement that the Bill and Melinda Gates Foundation will give up to $140 million to a Boston drug device manufacturer to develop an implantable mini-pump to deliver drugs for pre-exposure prophylaxis (PrEP) against HIV infection has focused attention on the future of PrEP. Is the future all about